Skip to main content

Table 1 Clinical characteristics of patients included

From: Dysregulated splicing factor SF3B1 unveils a dual therapeutic vulnerability to target pancreatic cancer cells and cancer stem cells with an anti-splicing drug

Characteristic

Samples (n = 75)

Age

 

Median 65, (range 32–76)

Sex

 Female

22 (29.3)

 Male

53 (70.7)

T stage

 T1

5 (6.7)

 T2

14 (18.79)

 T3

43 (57.39)

 T4

9 (12)

 NA

4 (5.3)

N stage

 N0

25 (33.3)

 N1

46 (61.3)

 NA

4 (5.3)

M stage

 M0

62 (82.7)

 M1

7 (9.3)

 MX

2 (2.7)

 NA

4 (5.3)

  1. NA Not Available